Hepatitis E vaccine—Illuminating the barriers to use
Julia Lynch, Jacqueline Kyungah Lim, Philomena E. Peter Asaga, T. Anh Wartel, Melanie Marti, Beno Yakubu, Helen Rees, Kawsar R. Talaat, Brittany Kmush, Rakesh Aggarwal, Iza Ciglenečki, Emily S. Gurley, Alain Labrique
Abstract
Hepatitis E is likely the most common cause of acute viral hepatic disease globally. It is estimated that over 900 million people have been infected with hepatitis E virus (HEV), equivalent to nearly 1 in 8 individuals worldwide [1]. Available evidence suggests that 20 million people are infected annually resulting in over 70,000 deaths [2]. Considering the limited availability of diagnostics, insufficient surveillance, and investigation of hepatitis outbreaks, these are likely significant underestimates.
Topics & Concepts
OutbreakHepatitis E virusHepatitis EGenotypeHepatitis AMedicineEnvironmental healthDiseaseTransmission (telecommunications)VirologyPandemicHepatitisBiologyImmunologyInfectious disease (medical specialty)Coronavirus disease 2019 (COVID-19)Internal medicineGeneElectrical engineeringBiochemistryEngineeringHepatitis Viruses Studies and EpidemiologyLiver Disease and TransplantationViral gastroenteritis research and epidemiology